You already know the usual list. Telemedicine shifts. Expert witness work. Chart review. A consulting gig with a device company. Every one of them pays well, and every one of them stops paying the moment you stop working. That is not a side income problem. That is a ceiling problem.

Search “physician side income ideas,” and you will get the same fifteen articles reshuffled: pick up a few locum shifts, sign up for a telehealth platform, take a chart review gig on the side, maybe write for a medical content mill. Useful information, and none of it wrong. But almost all of it treats your years of training as a faster clock to bill against, not as a form of capital in its own right. Nobody asks the more interesting question: what happens to your judgment once the shift ends? Right now, for most physicians, the answer is nothing. It evaporates until the next shift.

There is a second path that most physician side income guides never mention, because most of them are written by people who have never built the infrastructure to offer it. It is the path from expertise to equity: taking the same clinical judgment you are already renting out by the hour and turning it into ownership in the companies building the future of health, dental, and wellness care. It is a fundamentally different relationship to your own expertise, one where the thing you know keeps working for you long after you have logged off, gone home, and moved on to the next patient.

Quick answer: The most common physician side income ideas- telemedicine, expert witness work, chart review, consulting, pay well but cap at your hourly rate. The next tier is equity: joining a vetted clinician investor network where your clinical judgment earns you board seats, advisory equity, and direct ownership in the healthcare companies you help build.

What Are the Most Common Physician Side Income Ideas Right Now?

Before we get to the part most people skip, let us be honest about what is already out there, because it is not bad advice. It is just incomplete.

Clinical Side Income

Locum tenens shifts, telemedicine platforms, urgent care moonlighting. You are still trading clinical hours for a rate, just on your own schedule.

Expertise-Based Income

Expert witness work, medical legal chart review, independent medical examinations. IMEs typically pay $500 to $2,000 per exam depending on specialty. Chart reviews run $150 to $400 per review. Steady, but project by project.

Consulting and Advisory Work

Pharma and device advisory boards, healthcare market research panels through networks like GLG or Guidepoint. This is the closest most clinicians get to “strategic” work, and it is usually a single meeting with a stipend attached, not an ongoing stake in the outcome. If you want advisory roles with real input, the structure looks meaningfully different.

Content and Teaching

Medical writing, CME development, tutoring. Creative and flexible, but the ceiling is your writing speed, not your clinical judgment.

Passive Investment Vehicles

Rental property, index funds, dividend portfolios, the occasional angel check written on a friend’s recommendation with no real vetting behind it. These are not “side income” in the traditional sense, since they usually do not involve active work, but physicians reach for them for the same reason they reach for locum shifts: they are familiar, they are widely recommended, and they require no new infrastructure to access. The tradeoff is that familiarity is exactly why the returns are capped. Everyone has access to the same index fund. Nobody is pricing your clinical judgment into a REIT.

Taken together, these five categories cover almost every physician side income idea in circulation today. They are not a bad starting point. Many clinicians use two or three of them at once, stacking a few locum shifts with a chart review contract and a rental property, and calling it diversification. The problem is not that any single one of these is a poor choice. The problem is that none of them changes the fundamental math of how a physician gets paid: hours in, dollars out, with a hard ceiling set by how many hours exist in a week and how much any single hour is worth.

Side Income Type	Typical Rate	Time Commitment	Ceiling
Locum tenens / telemedicine	$80 to $200/hr	Shift based	Capped at hourly rate
Expert witness / IME	$500 to $2,000/case	Project based	Capped at case volume
Chart review	$150 to $400/review	Project based	Capped at review volume
Advisory board (pharma/device)	Stipend, often $1,000 to $5,000/meeting	A few hours/quarter	Capped, no equity
Medical writing / CME	Varies by project	Flexible	Capped at output
Startup equity (vetted)	2 to 10x on capital, over the life of the investment	Ongoing, but not hourly	Uncapped, compounds with the company

Why Do These Side Income Streams Have a Ceiling?

Every option above shares one trait: value stops compounding the moment you stop showing up. Raise your rate all you want, the math is still hours times dollars. Equity works differently. You do the work once, at the point of investment and advisory input, and the value keeps building whether you are in the room that week or not.

Think about what actually happens when you take on a second locum shift next month. You add hours, so you add income, in a straight line. There is no version of that shift where the work you did in March keeps generating income in October without you lifting a finger again. Compare that to a founder who took your feedback on a clinical protocol eighteen months ago. If that protocol became the foundation of the product, your input from that one conversation is still generating value today, and it will keep generating value as the company grows, whether or not you have spoken to that founder since.

This is the distinction that most physician financial advice glosses over. It treats “passive income” as a single category, lumping rental property, dividend stocks, and equity together as if they behave the same way. They do not. Rental property still requires active management, even with a property manager absorbing the day-to-day. Dividend stocks pay out a fixed, modest yield regardless of how sharp your read on the underlying business is. Equity in a company you actually helped shape is the only vehicle on that list where your specific expertise, not just your capital, is what is compounding.

What Does “Real Equity” Actually Mean for a Clinician?

You have probably already had the other kind. The advisory board seat that used your name on a slide and never asked your opinion again. The “strategic advisor” title with no equity attached. That is window dressing, not equity.

Real equity, not a name on a slide, means three things: an actual ownership stake, a real vote in the decisions that matter, and alignment where the company only wins if you were right about it. Clinicians who join our ecosystem tell us the same thing every time. They did not want to be passive anymore. They wanted their expertise to directly shape where a company goes, not decorate its pitch deck.

Why Startup Equity Beats Other Passive Income (for You, Specifically)

Most passive income advice funnels clinicians toward the same handful of vehicles: index funds, bonds, rental property, maybe crypto if you are feeling aggressive. Here is what those actually returned over the last five years.

The S&P 500 averaged roughly 15 to 20% annualized total return from 2021 through 2025, even after a rough 2022. Bonds did not keep pace. The five year annualized return sat near flat, essentially zero, after the 2022 selloff was the worst year for bonds on record. House flipping ROI came in at the lowest since 2008 at 25.5% gross in 2025, and that figure is before rehab costs, which typically run 20 to 33% of after repair value. These are steady, capped, well understood returns. That is the point of them, and there is nothing wrong with holding them.

Startup equity works differently. When you back a health, dental, or wellness company, you are not buying a ticker. You are pricing a clinical claim with years of pattern recognition nobody on Wall Street has. A well vetted deal that succeeds typically lands in the 2 to 10x range on the capital invested, over the life of the investment, not annualized. That is a materially different upside than anything on the list above.

Here is the catch nobody tells you. Most startup investments have unfavorable odds without proper diversification and vetting: roughly 65% of startup investments return less than the capital put in, and only about 4% ever clear 10x. Most funds get those odds because they are betting on market timing and a business model that worked before, not on whether the specific people running the company can actually execute the plan they pitched.

That is the part we built our leadership evaluation process to solve. We run a proprietary leadership execution risk evaluation on the founder, the executive team, and the board before a deal ever reaches you, using a combination of assessments far more reliable than the survey based personality testing most funds still lean on, which is one dimensional and the least predictive method available. Where a typical fund spends four to six months just deciding which team is worth backing, we do it in a fraction of that time, because we are not guessing. That is how a clinician in our ecosystem gets closer to the 2 to 10x tier with fewer, better chosen positions, instead of needing ten scattered bets to hit the averages.

And it is not a stretch for you either way. You already choose the method that prevents disease over the one that is just familiar. Backing the company building that method is the same instinct. You are just finally getting paid for being right about it.

How Do Clinicians Get From Side Income to Startup Equity?

We built the infrastructure so you do not have to build it yourself. Three things happen before a company ever reaches you.

We vet the company first. Clinical truth, capital readiness, and the execution gaps most due diligence misses, including the leadership evaluation described above.

We match you by specialty, stage, and goals. Not a mass pitch deck blast. A short list of companies that actually fit what you know and what you are trying to build.

We stay with you after the check clears. Post investment support and milestone tracking, so your equity is not a one time bet into a black box.

Who Qualifies to Move From Side Income to Equity Ownership?

If you are already earning $250K or more, already doing some form of consulting or advisory work, and ready to invest with guidance, you are likely closer than you think. Core membership is built for accredited clinicians ready to start. Circle membership is for clinicians with higher net worth who want priority deal access and a bigger table.

What Does This Look Like in Practice?

Here is the pattern we see constantly in our ecosystem. A clinician spends years on a nonprofit board, or carries a “leader” or “executive” title at some coalition or association. Real responsibility, real hours, zero equity. It is volunteer work wearing a title. You showed up to every meeting, shaped real decisions, and walked away with nothing but a line on your CV.

The shift happens when that same clinician steps into an actual startup and, for the first time, negotiates for equity and revenue share instead of accepting another honorary seat. That is the moment they stop treating themselves like unpaid staff and start treating their judgment like the asset it is. Once you have made that shift once, you do not go back to trading your name for nothing.

Take Dr. Ardy Hakhamian, DDS, MPH, FIADFE, a dentist who spent years running a private practice and hiring other dentists, only to watch good associates leave every time family life pulled them elsewhere. Patient volume was never the problem. Keeping a stable team was.

That is what pushed him to start advising other dental offices on the innovations that actually move outcomes: better imaging, earlier detection of dental caries, smarter antibiotic selection, sleep apnea screening, oral systemic health protocols. That advisory instinct is now equity and leadership across five companies: Co-Founder and CSO at LEE, CSO at Focus Intl, CSO at Top Doctor Magazine, and roles with GT Cardio, BlockHaven.ai, and Scriptura Health, plus CEO of Dentulu Smiles Foundation and a Regent seat at Global Summit Institute.

He did not leave dentistry. He stopped being the only person capturing the upside of his own judgment.

To see more clinicians in our ecosystem who have made the same shift, visit our partnership and alignment page.

Key Takeaways

• Physician side income ideas like telemedicine, expert witness work, and consulting cap out at an hourly rate.
• Real wealth building for clinicians comes from equity and board influence, not more billable hours.
• Startup equity is passive in that you are not trading more hours for it, but it is driven by your clinical judgment in a way index funds and bonds never are.
• A well vetted startup deal typically returns 2 to 10x on capital invested. Most unvetted deals do not, which is why diversification across at least ten positions is the industry standard, and why our leadership evaluation process exists to shorten that odds gap.
• Real equity means real input. Not a name on an advisory slide.

FAQ

CTA

See if you qualify for Core or Circle membership. Apply now →

Want to see the model in action first? Join our next Mastermind →

About the Author

Sabrina Runbeck Chief Strategy Officer, Health Board Advisors

Sabrina Runbeck is a clinician turned business strategist, TEDx speaker, and 3x bestselling author. As Chief Strategy Officer at Health Board Advisors, she has lived both sides of this article, the side income grind and the path to real equity, and built the vetting infrastructure that gets clinicians from one to the other faster and with less risk.

Most healthcare business plans do not fail because the underlying idea is weak. They fail because the document does not communicate the right things to the right people in the right order.

Investors who evaluate healthcare ventures consistently report the same experience: they receive plans that describe a compelling clinical problem, propose a plausible solution, and then spend the remaining pages on market size projections and financial models built on assumptions that no one who has operated inside a health system would recognize as realistic.

The plan is not dishonest. It is simply written by someone who understands the clinical problem better than they understand what investors in healthcare specifically need to see before they take a meeting seriously.

This article is a practical guide to writing a healthcare business plan that investors will actually read, engage with, and use as the basis for a serious conversation. It covers what makes healthcare plans structurally different from plans in other industries, what each section needs to accomplish, and where most founders make the mistakes that cause plans to get set aside before the second page.

Why Most Healthcare Business Plans Get Set Aside

The most common reason a healthcare business plan fails to generate investor interest is not a weak idea or an unconvincing market size. It is that the plan does not demonstrate that the founder understands the specific dimensions of risk that healthcare investors are trained to look for.

Healthcare investment carries a set of structural risks that other sectors do not. Clinical validation requirements, regulatory pathways, reimbursement complexity, procurement timelines inside health systems, and the behavior of clinical buyers under real workflow conditions are all risk factors that generalist business planning frameworks do not account for and that generic business plan templates do not include.

By 2025, standardized VC intake forms had made a structured company synopsis an expected section, not an optional one. Investors reading a healthcare plan in the current environment are looking for evidence that the founder has done the domain-specific work, not just the market research work.

When a healthcare business plan arrives without a credible clinical validation section, without a realistic regulatory pathway description, and without a reimbursement strategy that reflects how payers actually make coverage decisions, it signals to an experienced healthcare investor that the founder’s understanding of the problem has not yet translated into an understanding of the execution path. That signal, however unintentionally sent, is usually sufficient to move the plan into the review-later pile.

The good news is that these gaps are fixable. Writing a healthcare business plan that investors will actually read is not about producing a longer or more polished document. It is about understanding what each section needs to communicate about your specific venture and writing to those requirements rather than to a generic business plan template.

What Makes a Healthcare Business Plan Different From Any Other

Before getting into specific sections, it is worth being precise about why healthcare business plans require a different approach from plans in other sectors.

In most industries, the primary questions a business plan needs to answer are: Is the market large enough? Is the product differentiated? Can the team execute? Can the unit economics support a scalable business?

Those questions matter in healthcare too. But healthcare adds a second layer of questions that must be answered before the first layer is credible:

Is the clinical claim substantiated, and by what standard of evidence? Does the regulatory pathway the company is planning to follow apply to their specific product category? Will payers reimburse the product, and under what conditions? Will clinical buyers actually change their workflow to adopt this, and what does the evidence say about adoption in comparable categories?

Malpractice suits and changing healthcare regulations are risks specific to the healthcare field that investors know you have considered what could go wrong and that you have a plan for dealing with challenges.

A healthcare business plan that does not address those questions specifically and credibly is not investor-ready regardless of how strong the market analysis or financial projections are. The clinical and regulatory foundation has to be established before the commercial case is convincing.

The Executive Summary: The Only Section Most Investors Read First

Investors tend to read your executive summary to get a sense of whether to read on and consider your request. In healthcare specifically, an executive summary that does not signal clinical credibility and regulatory awareness in the first two paragraphs rarely generates enough interest to carry the reader into the body of the plan.

A strong executive summary for a healthcare business plan accomplishes four things in two pages or fewer:

States the clinical problem with precision. Not “healthcare is inefficient” or “patients are underserved.” A specific, documented clinical problem with a defined population, a measurable consequence, and evidence that the problem is real at the scale you are claiming. The more specific the problem statement, the more credible the plan.

Describes the solution and its clinical basis. What the product or service does, why it addresses the stated problem, and what the evidence basis is for the clinical claim. This does not need to be exhaustive in the executive summary, but it needs to signal that a clinical validation foundation exists.

Identifies the regulatory and reimbursement pathway. One or two sentences that demonstrate the founder knows which regulatory framework applies and what the reimbursement path looks like. This is the signal most healthcare investors are looking for in the first two pages that distinguishes plans worth reading from plans worth deferring.

States the funding ask with specific use of proceeds. How much capital is being raised, what stage it takes the company to, and what the specific milestones are that the capital is designed to achieve. Vague funding asks signal that the founder has not done the milestone planning that serious capital deployment requires.

Clinical Validation: The Section That Separates Credible Plans From Plausible Ones

For most healthcare investors, the clinical validation section is where the plan either earns or loses credibility. It is also the section most founders write last, briefly, and with the least rigor.

Clinical validation in a business plan does not mean a completed clinical trial. It means a documented, credible strategy for establishing that the product does what it claims to do, at the evidence standard that the regulatory pathway and the commercial buyers require.

What this section needs to include:

Current validation status. What evidence exists today that the clinical claim is valid? This could be published research in adjacent categories, a pilot with documented outcomes, expert clinical endorsement from relevant practitioners, or preliminary data from an internal study. Be specific about what you have and what it demonstrates.

Validation roadmap. What studies or pilots are planned, who will conduct them, what the timeline is, and what the evidence standard is designed to meet. If you are pursuing FDA clearance, the validation roadmap should be designed around the evidence requirements for your specific pathway. If you are pursuing payer reimbursement, the evidence standard should reflect what payers in your category require for coverage decisions.

Clinical advisory structure. Who is providing clinical oversight of the validation strategy, and what is their relevant domain expertise? A clinical advisor with direct experience in your specific indication, regulatory pathway, or clinical setting is a meaningful signal of validation credibility. A general medical advisory board with no specific connection to your clinical problem is not.

Investors who have funded healthcare companies before know that clinical validation is where most early-stage healthcare ventures are most exposed. A plan that addresses that exposure honestly, with a realistic strategy for building the evidence base the company needs, is considerably more credible than one that describes the clinical problem compellingly and then moves quickly to market size.

The Regulatory and Reimbursement Section Most Founders Underwrite

This is the section where the gap between founder knowledge and investor expectation is most consistently wide, and where the most correctable mistakes happen.

Regulatory and reimbursement strategy in a healthcare business plan is not a formality. It is the section that tells an experienced investor whether the founder understands the actual execution path for their specific product in their specific market.

Regulatory pathway. Identify the specific regulatory framework that applies to your product. For devices and software, this means identifying the relevant FDA classification, the applicable predicate devices if you are pursuing a 510(k) clearance, and the timeline for the submission process based on your current validation status. For digital health tools, this means understanding whether your product meets the definition of a Software as a Medical Device under the FDA’s Digital Health Center of Excellence framework and what that means for your clearance requirements.

Founders who write “we will seek FDA approval” without specifying the pathway, the classification, or the timeline signal to investors that the regulatory strategy has not been developed beyond the acknowledgment that regulation exists.

Reimbursement strategy. Identify the specific CPT codes or reimbursement pathways that apply to your product or service, the current coverage status of those codes, and the evidence standard that CMS or commercial payers require for coverage decisions in your category. If your product requires a new reimbursement pathway, describe the process and the realistic timeline for achieving it.

Your revenue projections need to account for a gap between opening and full payer access. Healthcare businesses that model revenue beginning at launch without accounting for the credentialing and payer contract activation timeline produce financial projections that experienced investors immediately recognize as unrealistic.

Market Analysis That Reflects How Healthcare Actually Works

Healthcare market analysis fails investors when it treats the market as a homogeneous addressable population rather than as a series of distinct buyer segments with different decision-making processes, different procurement timelines, and different evidence requirements.

The total addressable market figure that anchors most healthcare business plans is rarely the number that matters to a sophisticated investor. What matters is the serviceable addressable market: the specific segment of buyers your company can reach with its current product, go-to-market capacity, and clinical evidence at the stage you are in today.

A realistic healthcare market analysis for an investor-ready business plan includes:

Buyer segmentation. Who specifically buys your product: individual practitioners, physician groups, health systems, payers, or employer health benefit programs? Each of these buyer types has a different procurement process, a different decision timeline, and a different evidence standard for adoption decisions. Your market analysis should reflect the specific dynamics of your actual buyer segment, not a generic description of the healthcare market.

Competitive landscape with clinical specificity. Who else is attempting to solve the same problem, what is the current standard of care, and what does your clinical differentiation look like relative to existing solutions? A competitive analysis that identifies competitors by name and compares clinical evidence, regulatory status, and commercial traction is considerably more credible than one that describes the market as “fragmented” and identifies the company’s advantage as “better technology.”

Adoption dynamics. What does the evidence say about clinical adoption in comparable product categories? What is the typical sales cycle length for your buyer segment? What are the primary barriers to adoption and how does the company’s go-to-market strategy address them? Healthcare investors who have funded companies that failed at the commercial stage are specifically looking for evidence that the founder has thought through the adoption problem with the same rigor they applied to the clinical problem.

Financial Projections Investors Will Believe

Financial projections in a healthcare business plan are not primarily about optimism. They are about demonstrating that the founder understands the financial mechanics of their specific business model and has built their projections on assumptions that reflect how healthcare revenue actually works.

The most common financial projection mistakes in healthcare business plans:

Revenue that begins at launch. The average credentialing timeline to activate commercial payer contracts means your revenue projections need to account for a gap between opening and full payer access. A financial model that shows revenue beginning in month one without accounting for payer credentialing, health system procurement timelines, or clinical validation requirements signals that the revenue model has not been stress-tested against operational reality.

Unit economics that ignore clinical complexity. Customer acquisition cost in healthcare is structurally higher than in most other industries because of the regulatory, credentialing, and procurement friction that precedes adoption. A financial model that applies consumer or general software customer acquisition assumptions to a healthcare product will not survive the first serious investor question.

A single scenario without sensitivity analysis. Investors in healthcare expect founders to have modeled multiple scenarios because healthcare timelines are genuinely uncertain. A plan that presents a single financial projection without examining the impact of a regulatory delay, a longer-than-projected sales cycle, or a lower-than-projected adoption rate at the first health system pilot signals that the founder has not stress-tested their own assumptions.

Founders must know the exact cash buffer required to survive the operational ramp-up period. The cash requirement calculation, the break-even timeline, and the minimum runway assumption should all appear explicitly in the financial section with the logic behind each number documented.

The Team Section: Clinical Credibility on the Page

Your team can be more important than your product or service. In healthcare specifically, the team section is where investors assess whether the founding team has the specific combination of clinical, regulatory, operational, and commercial expertise to execute the plan they have written.

A strong healthcare business plan team section does not just list credentials. It maps the expertise of each team member to a specific execution requirement of the business.

The clinical founder’s background should connect to the specific clinical problem, patient population, and care setting the company is addressing. A cardiologist founding a remote cardiac monitoring company has a specific connection that matters. A physician with general clinical experience founding the same company needs to explain how that background translates into the domain-specific knowledge the company requires.

The regulatory and commercial expertise on the team should be documented with the same specificity. If the team does not yet have regulatory expertise internally, the plan should identify the advisory or consulting resources that will fill that gap and how those resources will be accessed and managed.

Clinical advisors named in the business plan should have specific domain relevance, not just impressive titles. A clinical advisory board that includes practitioners who have operated in the specific care settings, with the specific patient populations, or under the specific regulatory frameworks the company is addressing is a meaningful signal. A list of physicians with general clinical credentials is not.

How HBA Helps Founders Build Plans That Reach the Right Investors

Writing an investor-ready healthcare business plan is one challenge. Getting that plan in front of investors who are specifically positioned to evaluate it with clinical depth is a different one, and it is the challenge most founders find harder to solve.

Health Board Advisors was built to address both sides of that problem for healthcare founders.

The Pathfinder program provides a structured pre-investment evaluation that assesses clinical validity, regulatory positioning, commercial infrastructure, and founder execution readiness before any capital introduction is made. Rather than sending a business plan into an open submission process where it competes against hundreds of others, founders who go through Pathfinder enter investor conversations with a vetted evaluation already completed, which changes how those conversations begin.

The Capital Engine connects vetted healthcare founders with aligned investors through the Triple Match system: matching clinical vision, execution capability, and capital orientation before introductions are made. The investors inside the HBA ecosystem are clinicians, operators, and executives who evaluate clinical claims with the domain knowledge the plan requires, which means the conversations that follow a matched introduction are substantively different from those produced by generic investor outreach.

The expert directory gives founders access to vetted clinical advisors across FDA approval, clinical validation, go-to-market strategy, revenue cycle management, AI governance, and board governance who can strengthen the clinical advisory structure of the business plan before investor conversations begin.

Upcoming events including the monthly Hot or Not startup pitch sessions give founders direct access to the HBA investor community in a structured format before formal capital conversations begin. All events are listed at healthboardadvisors.com/events.

Connect with HBA

Health Board Advisors works with healthcare founders who are ready to build investor-ready ventures, not just investor-ready documents. Through vetted clinical advisory matching, structured pre-investment evaluation, and aligned capital introductions, HBA provides the infrastructure that turns a strong healthcare business plan into a funded company.

Connect with HBA →

Or learn more about the Pathfinder program to understand how HBA evaluates and prepares founders for investor conversations.

About the Author

Sabrina Runbeck, MPH, MHS, PA-C
Chief Strategy Officer, Health Board Advisors

Sabrina Runbeck is Chief Strategy Officer at Health Board Advisors, where she helps unite physician-investors, operators, and founders to build and scale healthcare companies with clinical integrity. She is a healthcare strategist with 24 years of experience in clinical medicine, public health, executive coaching, and strategic consulting, drawing on a decade spent as a cardiothoracic surgery physician associate before pivoting into venture strategy and advisory work. 

She has promoted more than 250 founders and industry leaders on Provider’s Edge, a podcast ranked in the top 5% globally, and is a TEDx speaker and media expert featured on FOX, CBS, and ABC. She’s also co-founder of PulsePoint Path and the Health Tech Impact Awards, and serves as a judge for healthcare pitch competitions such as the Global Innovation in Women’s Health Pitch Showcase.

Related Articles

Want to understand how HBA evaluates your venture before introducing you to investors? Read about the Pathfinder program and the Founder Execution Risk Filter to see how clinical validity, regulatory positioning, and founder execution readiness are assessed before any capital introduction is made.

Frequently Asked Questions